|
The incidence of respiratory symptoms as reported by symptom diary during 7 days following challenge for the safety population |
||
| Symptom / beta2agonist use |
Mannitol |
Hypertonic Saline |
|
|
||
| n |
627 (%) |
636 (%) |
| Daytime cough |
352 (56.9) |
365 (58.4) |
| Wheeze |
270 (43.6) |
280 (44.8) |
| Trouble breathing |
270 (43.6) |
262 (41.9) |
| Symptoms interfering with activities |
172 (27.8) |
178 (27.4) |
| Night time cough |
212 (34.2) |
236 (37.8) |
| Beta2 agonist use |
319 (51.5) |
333 (53.3) |
| Nebulised beta2 agonist |
16 (2.6) |
19 (3.0) |
Brannan et al. Respiratory Research 2005 6:144 doi:10.1186/1465-9921-6-144 |
||